PONV stands for postoperative nausea and vomiting in adults, which affects roughly 16 million patients annually in the U.S. Enduring surgery is hard enough, and no one should have to deal with nausea and vomiting on top of it. Thankfully, a recent Medscape article discussed a new option to treat PONV. The FDA just approved amisulpride injection, aka Barhemsys from Acacia Pharma, which is the first and only green-lit antiemetic intended to treat PONV. Acacia expects to launch the new injection in the second half of 2020.
Quick Hits: FDA Approves Anti-Nausea Post-Op Injection
16 million Americans suffer from post-op nausea and vomiting each year.
Mar 6, 2020
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More